This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Robust Biopharmaceutical Pipeline Offers New Hope For Patients

"Since 2005, the number of new medicines in development has grown by 40 percent," said John Lechleiter, Ph.D., chairman of PhRMA and chairman, president, and CEO of Eli Lilly and Company. "Our industry has been able to advance scientific discovery – along with the roster of potential new medicines – thanks, in part, to a policy environment that enables medical innovation to flourish. Public policies that value intellectual property, a strong regulatory system, and free market access for patients are critical to maintaining a robust innovation ecosystem and continuing to make progress fighting disease."

"On the eve of the presidential inauguration and in the midst of challenging fiscal pressures, we should renew our focus on the benefits of medical innovation for patient care, the economy and U.S. jobs," continued Castellani.  "The President has continually stressed the importance of innovation as a cornerstone to improving health and the U.S. economy, but to achieve these goals, we need patient-centric policies and continued collaboration among the public and private sectors."

The biopharmaceutical research sector currently supports nearly four million jobs in the U.S. and the overall impact of the sector on the domestic economy is $917 billion annually.  What's more, over the last decade, PhRMA member companies alone have invested $500 billion in research and development of new therapies for a wide range of diseases such as diabetes, heart disease and HIV/AIDS. 

The full report by the Analysis Group, as well as an accompanying report developed by PhRMA, are available on our website (

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country's leading innovative biopharmaceutical research and biotechnology companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. Since 2000, PhRMA member companies have invested over $500 billion in the search for new treatments and cures, including an estimated $49.5 billion in 2011 alone.

Find PhRMA Online:

For information on how innovative medicines save lives, visit:

For information on the Partnership for Prescription Assistance, visit:

For information on ensuring the flow of medicines during public health emergencies, visit

SOURCE Pharmaceutical Research and Manufacturers of America

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs